Emmaus Life Sciences Inc (OTCQX:EMMA) CEO Yutaka Niihara tells Proactive it revealed positive transfusion data from a post-hoc analysis of its Phase 3 study of Endari in patients with sickle cell disease. Endari is a prescription L-glutamine oral powder that is approved by the FDA to reduce complications of sickle cell disease. Niihara says analysis of the Phase 3 data indicated that patients who got blood transfusions required 43% fewer units of red blood cells when treated with Endari.
Emmaus Life Sciences reveals new Phase 3 data of its drug Endari in sickle cell patients
